Methods of treating androgenic alopecia with finasteride

Methods of treating androgenic alopecia with finasteride

United States Patent	5,571,817
Rasmusson, et. al.	Nov. 5, 1996

Methods of treating androgenic alopecia with finasteride [17.beta.-N-mono-substituted-carbamoyl-4-aza-5-.alpha.-androst-1-en-ones]

Inventors:	Rasmusson; Gary H. (Watchung, NJ); Reynolds; Glenn F. (Westfield, NJ).
Assignee:	Merck & Co., Inc. (Rahway, NJ).
Appl. No.:	94,815
Filed:	Jul. 20, 1993

Related U.S. Application Data

Continuation of (including streamline cont.) Ser. No. 16,476, Feb. 10, 1993, abandoned, which is a continuation of Ser. No. 927,256, Aug. 7, 1992, abandoned, which is a continuation of Ser. No. 698,374, May 9, 1991, abandoned, which is a continuation of Ser. No. 545,676, Jun. 28, 1990, abandoned, which is a continuation of Ser. No. 370,142, Jun. 21, 1989, abandoned, which is a continuation of Ser. No. 198,708, May 19, 1988, abandoned, which is a continuation of Ser. No. 34,806, Apr. 3, 1987, abandoned, which is a continuation-in-part of Ser. No. 800,623, Nov. 21, 1985, Pat. No. 4,760,071, which is a continuation of Ser. No. 584,062, Feb. 27, 1984, abandoned.

Intl. Cl. :	A61K 31/44
Current U.S. Cl.:	514/284; 546/77
Field of Search:	546/77; 514/284

References Cited | [Referenced By:]

U.S. Patent Documents

2,227,876	Jan., 1941	Bolt	260/269
3,239,417	Mar., 1966	Tullio et al.	167/65
3,264,301	Aug., 1966	Doorenbos et al.	260/286
3,285,918	Nov., 1966	Doorenbos et al.	260/251
4,139,619	Feb., 1979	Chidsey, III	424/45
4,220,775	Sept., 1980	Rasmusson et al.	546/77
4,317,817	Mar., 1982	Blohm et al.	424/226
4,377,584	Mar., 1983	Rasmusson et al.	424/258
4,396,615	Aug., 1983	Petrow et al.	424/242
4,596,812	Jun., 1986	Chidsey, III et al.	514/256
4,689,345	Aug., 1987	Kasha et al.	514/546
4,732,897	Mar., 1988	Cainelli et al.	514/222
4,760,071	Jul., 1988	Rasmusson et al.	514/284
4,845,104	Jul., 1989	Carlin et al.	514/284
4,859,681	Aug., 1989	Rasmusson et al.	514/284
4,882,319	Nov., 1989	Holt et al.	514/119
4,888,336	Dec., 1989	Holt et al.	514/278
4,910,226	Mar., 1990	Holt et al.	514/573
5,021,575	Jun., 1991	King et al.	546/77
5,049,562	Sept., 1991	Rasmusson et al.	514/284
5,061,802	Oct., 1991	Steinberg et al.	546/77
5,075,450	Dec., 1991	Rasmusson et al.	546/285
5,084,574	Jan., 1992	Bhattacharya et al.	546/77
5,091,380	Feb., 1992	Rasmusson et al.	514/169
5,120,729	Jun., 1992	Chabala et al.	514/210
5,120,742	Jun., 1992	Rasmusson et al.	514/284
5,138,063	Aug., 1992	Rasmusson et al.	546/77
5,151,429	Sept., 1992	Rasmusson et al.	514/284
5,151,430	Sept., 1992	Steinberg et al.	514/284
5,162,332	Nov., 1992	Steinberg et al.	514/284
5,175,155	Dec., 1992	Juniewicz et al.	514/176
5,196,411	Mar., 1993	Rasmusson et al.	514/169

Foreign Patent Documents

970692	Jul., 1975	CA
0004949	Oct., 1979	EP
0155096	Sept., 1985	EP
0277002	Aug., 1988	EP
0289327	Nov., 1988	EP
0314199	May, 1989	EP
0343954	Nov., 1989	EP
0375347	Jun., 1990	EP
0375349	Jun., 1990	EP
0375345	Jun., 1990	EP
0375344	Jun., 1990	EP
0463638	Jan., 1992	EP
1465544	Nov., 1965	FR
59-13719	Jan., 1984	JP
60-116657	Jun., 1985	JP
60-126218	Jul., 1988	JP
83/7859	Nov., 1984	ZA
WO85/05272	Dec., 1985	WO
WO85/05270	Dec., 1985	WO

Other References

Orentreich, Ann. Plast. Surg. (United States), Jan. 1978, pp. 116-118, "Medical treatment of baldness".

Questel. Orbit, JAPIO file (abstract), accession No. 84-013719 (1984).

Derwent WPAT file (abstract), accession No. 85-200306/33 (1985).

Questel. Orbit, JAPIO file (abstract), accession No. 85-116657 (1985).

Neri, et al., "A Biological Profile of Nonsteroidal Antiandrogen, SCH 13521", Endo., vol. 91, No. 2, pp. 427-437 (1972).

Nayfeh, et al., "Metabolism of Progesterone by Rat Testicular Homogenates", Steroids, vol. 14, pp. 269-283 (1969).

Voigt, et al., Endo., vol. 92, p. 1216.

Doorenbos, et al., "Synthesis and Antimicrobial Properties of 17 Beta-Isopentyloxy . . . ", J. Pharm. Sci., vol. 62, No. 4 pp. 638-640 (1973).

Doorenbos, et al., "4-17 Alpha-Dimethyl-4-Aza-5 Alpha-Androstan-17 Beta-ol-Acetate . . . ", J. Pharm. Sci., vol. 60, No. 8, pp. 1234-1235 (1971).

Doorenbos, et al., "Synthesis and Evaluation of Antimicrobial Properties . . . ", J. Pharm. Sci., vol. 63, No. 4, pp. 620-622 (1974).

Back, et al., "N-Chloroazasteroids: A Novel Class of Reactive Steroid Analogues", J. Org. Chem., vol. 54, pp. 1904-1910 (1989).

Liang, et al., "Inhibition of 5 Alpha-Reductase, Receptor Binding and Nuclear Uptake of Androgens . . . ", Chem. Abs., vol. 95, No. 13, p. 99, AB #109055j (1981).

Brooks, et al., "Prostatic Effects Induced in Dogs by Chronic or Acute Oral Administration . . . ", The Prostate, vol. 9, pp. 65-75 (1986).

Kadohama, et al., "Retardation of Prostate Tumor Progression in Nobel Rat . . .", J NCI, vol. 74, No. 2, pp. 475-486 (1985).

Andriole, et al., "The Effect of 4MA, a Potent Inhibitor of 5 Alpha-Reductase . . . ", The Prostate, vol. 10, pp. 189-197 (1987).

Bingham, et al., "The Metabolism of Testosterone By Human Male Scalp Skin", J. Endocr. (England), vol. 57, pp. 111-121 (1973).

Kedderis, et al., "Studies with Nitrogen-Containing Steroids and Freshly Isolated Rat Hepatocytes", Tox. Appl. Pharm., vol. 93, pp. 403-412 (1988).

Liang, et al. "Species Differences in Prostatic Steroid 5-Alpha Reductases . . . ", Endocrinology, vol. 117, pp. 571-579 (1985).

Stone, et al., "Estrogen Formation in Human Prostatic Tissue from Patients . . .", The Prostate, vol. 9, pp. 311-318 (1986).

Brooks, et al., "5 Alpha Reductase Inhibitory and Anti-Androgenic Activities . . . ", Steroids, vol. 47, pp. 1-19 (1986).

Labrie, et al., "Combination Therapy in Prostate Cancer", Lancet, vol. 2, #8515, pp. 1095-1096 (1986).

Rasmusson, et al., "Azasteroids: Structure-Activity Relationships for Inhibition . . . ", J. Med. Chem., vol. 29, pp. 2298-2315 (1986).

Rasmusson, et al., "Azasteroids as Inhibitors of Rat Prostatic 5-Alpha Reductase", J. Med. Chem., vol. 27, pp. 1690-1701 (1984).

Rittmaster, et al., "The Effects of N,N-Diethyl-4-Methyl-3-Oxo-4-Aza-5-Alpha Androstane . . . " J. Clin. Endo. & Metab., vol. 65, pp. 188-193 (1987).

Metcalf, et al., "Potent Inhibition of Human Steroid 5 Alpha-Reductase . . . ", Bioorganic Chem., vol. 17, pp. 372-376 (1986).

Levy, et al., "Inhibition of Rat Liver Steroid 5 Alpha-Reductase by 3-Androstene . . . ", Biochemistry, vol. 29, pp. 2815-2824 (1990).

Holt, et al., "Steroidal A Ring Aryl Carboxylic Acids . . . ", J. Med. Ch vol. 33, pp. 937-942 (1990).

Levy, et al., "Interaction Between Rat Prostatic Steroid 5 Alpha Reductase . . . ", J. Steroid Biochem, vol., 34, pp. 571-575 (1989).

Holt, et al., "Inhibition of Steroid 5 Alpha-Reductase by Unsaturated.", J. Med. Chem., vol. 33, pp. 943-950 (1990).

Metcalf, et al., "Inhibitors of Steroid 5 Alpha Reductase in Benign . . . ", TIPS, vol. 10, pp. 491-495 (1989).

Murphy, et al., "The Effect of Estradiol on a 25-Hydroxycholecalciferol Binding Protein . . . ", Steroids, vol. 35, pp. 1-7 (1980).

Diani, et al., "Hair Growth Effects of Oral Administration of Finasteride, a Steroid . . . ", J. Clin. Endo. & Metab., vol. 74, pp. 345-350 (1992).

Presti, Jr., et al., "Multicenter, Randomized, Double-Blind, Placebo Controlled Study . . . ", J. Urology.

Gormley, et al., "A Placebo Controlled Study of Finasteride (MK-906) on Stage D Prostate Cancer", Abst. of talk at Amer. Urol. Assoc. Mtg. in Canada (1991).

Gormley, et al., "Role of 5 Alpha Reductase Inhibitors in Treatment of Advanced Prostatic Carcinoma", Urol. Clinics of N. Amer., vol. 18, pp. 93-98 (1991).

Gormley, et al., "Effect of Finasteride on Serum PSA Levels in Men w/Prostate Cancer", 2nd Intnl. (Jan. 18, 1992).

Huggins, et al., "Studies on Prostatic Cancer", Cancer Research, pp. 293-297 (1941).

Rainwater, et al., "Prostate-Specific Antigen Testing in Untreated & Treated . . . ", Mayo Clinic Proc., vol. 65, pp. 1118-1126 (1990).

Arai, et al., "Prognostic Significance of Prostate Specific Antigen in Endocrine . . . ", J. of Urol., vol. 144, pp. 1415-1419 (1990).

Hudson, et al., "Clinical Use of Prostate Specific Antigen in Patients with Prostate Cancer", J. of Urol., vol. 142, pp. 1011-1017 (1989).

Brawer, et al., "Prostate-Specific Antigen in Management of Prostatic Carcinoma", Supp. to Urology, vol. 33, pp. 11-16 (1989).

Stamey, et al., "Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma . . . ", N. E. Jour. Med., vol. 317, pp. 909-916 (1987).

Walsh, et al., "The Value of Prostate-Specific Antigen in the Management . . . ", Ther. Prog. Urol. Can., pp. 27-33 (1989).

Stamey, et al., "Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma . . . ", J. of Urology, vol. 141, pp. 1070-1075 (1989).

Lange, et al., "The Value of Serum Prostate Specific Antigen Determinations . . . ", J. of Urol., vol. 141, pp. 873-879 (1989).

Hoehn, et al., "Human Prostatic Adenocarcinoma", The Prostate I, pp. 95-104 (1980).

Helliker, "Alopecia Sufferers Seek to Suffer Less . . . ", Wall Street Journal pp. A1-A7 (1991).

Chemical Engineering News, pp. 7-8 (29 Jun. 1992).

Allen & Hanburys Limited (Hayes') Appl (1977) RPC 113.

Television Transcript, News 4 New York Live at Five, WNBC-TV, NY, S. Simmons and M. Gomez (Nov. 29, 1993).

Primary Examiner: O'Sullivan; Peter
Attorney, Agent or Firm: Quagliato; Carol S., Winokur; Melvin, North; Robert J.

Abstract

17.beta.-N-monosubstituted-carbamoyl-4-5.alpha.-androst-1-en-3-ones of the formula ##STR1## wherein R(^1) is selected from hydrogen, methyl and ethyl and R(^2) is a branched chain alkyl of from 3-12 carbons, and R', R", R'" are hydrogen or methyl are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of androgenic alopecia.

2 Claims, No Drawings